# A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

*PRI Rank #1 · Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026/rank-1*

| Field | Value |
| --- | --- |
| Rank | #1 |
| 18m citations | 944 |
| Journal | New England Journal of Medicine |
| Year | 2024 |
| DOI | 10.1056/nejmoa2309000 |
| Corresponding authors | Stephen A Harrison |
| Institution | University of Oxford, United Kingdom |

**Ranking page:** [Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026](https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026)

**Paper link:** [10.1056/nejmoa2309000](https://doi.org/10.1056/nejmoa2309000)

## Topics

resmetirom · Steatohepatitis · Steatohepatitis · Liver fibrosis · thyroid hormone receptor beta-selective agonist · Steatohepatitis resolution · Liver fibrosis improvement · NAFLD Activity Score · F1B fibrosis · Fibrosis stage F2 · Fibrosis stage F3 · Biopsy-confirmed steatohepatitis · LDL cholesterol · 80 mg resmetirom · 100 mg resmetirom · liver-directed therapy · MAESTRO-NASH trial

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026. https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026. Accessed 2026-07-24.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```